Chief Commercial Officer“The Pessimist Sees Difficulty In Every Opportunity. The Optimist Sees Opportunity In Every Difficulty.” – Winston Churchill
May 5, 2020
Embody, Inc. Announces $9.3 M Series A Funding Round
Funds to Support Commercial Launch and Post-Market Clinical Studies of Tapestry® for serious tendon and ligament injuries.
Norfolk, VA, May 5th, 2020 — Embody, Inc., a privately-held medical device company focused on soft tissue repair, announced today that is closed a $9.3 million Series A funding round led by Litigit LLC, with participation from Cultivate(MD) and 757 Angels . The financing will enable Embody to expand its world-class team and the commercial launch Tapestry®, its next-generation soft-tissue repair technology in the second half of 2020.
“This financing represents a significant step in the growth of Embody” said Jeff Conroy, Embody’s Co-founder and Chief Executive Officer. “We are now in a position to execute on our goals of commercializing Tapestry, our first in a series of soft-tissue repair products for Achilles, rotator cuff and knee ligament injuries.”
The global market for sports medicine products is expected to reach $9 billion by 2024. Embody’s products focus on the most pressing patient needs: the repair of serious tendon and ligament injuries and are developed in close collaboration with some of the most advanced clinical thought leaders.
About Embody: Embody is pioneering the next generation regenerative platform for the repair of tendon and ligament injuries with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market. Founded in 2014 and funded with $20 million in DARPA & DOD funding, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair, including ACL (Anterior Cruciate Ligament).